Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

54.63 +0.27 (+0.50%)
Official Closing Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Dry January Investing: Trading Pints For Portfolio Growth
Around 15% of Americans said they were planning to participate in Dry January — a month of abstinence from alcohol — according to a survey. 
Via Benzinga
Short Sellers' Nightmare: $195B Evaporates In 2023's Market Surge
Short sellers had a bad year, with bets on the Mag7 tech giants showing the worst losses. 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Market Whales and Their Recent Bets on MRNA Options
Via Benzinga
2 Major Reasons Why Moderna (MRNA) Stock Is Up Today
One of the most beaten-down stocks of 2023 in the biotech space, Moderna is seeing a rebound today, with MRNA stock up 15%. 
Via InvestorPlace
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
Via Investor Brand Network
3 reasons 2024 Moderna shareholders may party like it's 2021
With interest in Moderna Inc. stock picking up alongside news flow, investors could be in for some very healthy 2024 gains. 
Via MarketBeat
Exposures COVID-19
2023 in Review: Key Stock Trends and Sector Shifts Unveiled
Investors would be smart to pay attention to these stock trends, many of which are taking hold as the New Year begins. 
Via InvestorPlace
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
These innovative biotechs likely aren't done rewarding their shareholders. 
Via The Motley Fool
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC. 
Via Benzinga
Topics ETFs
US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations
Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Apple, Longboard Pharmaceuticals, Coinbase, Moderna, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy... 
Via Benzinga
Topics Stocks
Exposures US Equities
2023's Biggest Losers In The Russell 1,000
In this article, we show 35 Russell 1,000 members that fell by at least 30% during the year 2023. 
Via Talk Markets
Tech Drags On Wall Street As 2024 Kicks Off; Dollar and Treasury Yields Surge: What's Driving Markets Tuesday?
Wall Street kicked off 2024 on a weaker note, with the S&P 500 dipping by 0.5%, and the Nasdaq 100 experiencing a 1.4% decline in midday trading in New York. 
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
What's Going On With Pfizer Stock?
Pfizer, Inc. (NYSE: PFE) shares are trading higher on the first trading day of 2024 after the stock lost more than 40% in 2023. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Tech Stalls As Rising Bond Yields Spook Investors
It's been an inauspicious start to the 2024 trading year, with all three major indexes in the red midday. 
Via Talk Markets
Moderna Analyst Projects Transformation Into 'Five-Product Commercial Company' By 2026
Moderna Inc (NASDAQ: MRNA) is back in focus as it is making advancements in cancer treatment. 
Via Benzinga
Moderna Stock Is Moving Higher: What's Going On?
Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday following positive analyst coverage from Oppenheimer. 
Via Benzinga
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
The pair's collaboration is making waves, and there's more to come. 
Via The Motley Fool
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations. 
Via Benzinga
Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High
The market looks set to end 2023 on a high note, but 2024 is less certain, particularly because though, the US does not want further action in the Gulf, it seems, Iran via its proxies is gaming for... 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Winners and Losers: 2023 Stock Market Performance Review
The 2023 stock market saw steep declines followed by rapid upswings, but we're ending the year on a high note (even if some stocks aren't). 
Via InvestorPlace
Why Is RayzeBio (RYZB) Stock Up 100% Today?
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Should You Buy This Year's Worst-Performing S&P 500 Stocks for 2024?
Some of this year's underperformers could have brighter futures. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
HBM Gets Health Boost From Drug Licensing Deals
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.